Maria Carvalho briefly discusses and provides 8 of the published, peer-reviewed stability studies of compounded medications with PCCA's SuspendIt. These studies were conducted by the researchers at Xavier University of Louisiana.

Members of PCCA's Clinical Services and PCCA Science teams provide a review of some of the research into the morbidity, mortality and pathogenicity of SARS-CoV-2. The information gathered is based on the best scientific evidence currently available regarding potential treatments. They also take the time to explore some potential non-prescription and prescription options based on their research.

Maria Carvalho, PharmD, MRPharmS, PhD, Manager of PCCA Science, provides an exciting update regarding treatment of oral lichen planus, a formulation study for surgical wound healing and a whole lot more in this PCCA Science Update!

Nat Jones of PCCA's Clinical Services Team discusses the clinical data about the efficacy of Permeation-enhanced topical pain therapy (PETPT) or transdermal pain therapy. He provides a brief history of transdermal pain therapy and evidence of the levels of efficacy PETPT has within medicine.

As long as COVID-19 is spreading in communities, everyone is encouraged to practice social distancing and face-covering, regular and thorough hand hygiene, appropriate respiratory hygiene, and good disinfection habits. PCCA Science has been researching published literature and would like to discuss what evidence is currently available regarding the questions revolving around hygiene, social distancing, and good disinfection habits.

Yi Liu, PCCA Research Pharmacist, provides an exciting update regarding new therapies, the extension of beyond-use dates (BUDs) for compounding formulations, evaluating compounding equipment and a whole lot more in this PCCA Science Update!

In the first part of this article, Pamela, Nat, and Sara shined a light on new health risk information compounders should consider when providing bioidentical hormone replacement therapy. In this second part of the article, they dive deeper into the BHRT conversation, discussing compounded topical estrogen as an option.

Compounded bioidentical hormone replacement therapy (BHRT) is an important treatment option for women around the world. Colleagues and patients alike come to PCCA experts Pamela Smith, Nat Jones and Sara Hover for guidance. In this article, our three experts cover this all-too-important topic in the HRT conversation, on what current literature says about the usage of oral vs. topical estrogen discussion.

Yi Liu, PharmD, PhD, PCCA Research Pharmacist has an exciting PCCA Science update on case studies, new product testing and comprehensive formula analysis revolving around our PCCA bases. Check it out!

We have developed a robust system to ensure that we create and maintain over 9,000 formulas that provide PCCA members with what they need to compound high-quality, pharmaceutically elegant customized medications for their patients — all while complying with the latest standards in pharmacy compounding. But what does that look like? What’s in a PCCA formula? Let's take a closer look.